ScrutarSign up free

ALNY SEC Filings

SEC filings for ALNY. Annual and quarterly reports, 8-K events, Form 4 insider filings and 13D/G stake disclosures.

All10-K10-Q8-KProxyForm 413D/GLast 12 months
FormFiledAccession
4SUPRAN BRYANEVP, CLO and SecretaryOct 7, 2026EDGAR
4Greenstreet YvonneChief Executive OfficerSep 22, 2026EDGAR
10-QAIAlnylam reports very strong growth, driven by AMVUTTRA in ATTR-CM: revenue up 67% for the quarter, a swing to net income, and a confident Alnylam 2030 strategy.Jul 30, 2026EDGAR
8-KJul 30, 2026EDGAR
4PYOTT DAVID E IJun 3, 2026EDGAR
8-KAIAlnylam Pharmaceuticals expanded its Board of Directors from ten to eleven members, electing Benjamin F. Cravatt, Ph.D.May 27, 2026EDGAR
4Sigal Charles ElliottMay 22, 2026EDGAR
4SCHULMAN AMY WMay 22, 2026EDGAR
4Reitan Colleen FMay 22, 2026EDGAR
4PYOTT DAVID E IMay 22, 2026EDGAR
4KELLOGG PETER NMay 22, 2026EDGAR
4HAMBURG MARGARET AMay 22, 2026EDGAR
4BRANDICOURT OLIVIERMay 22, 2026EDGAR
4Ausiello Dennis AMay 22, 2026EDGAR
4Arbuckle Stuart AMay 22, 2026EDGAR
4SCHULMAN AMY WMay 14, 2026EDGAR
SC 13G/AamendedCapital World InvestorsMay 14, 2026EDGAR
SC 13G/AamendedCapital Research Global InvestorsMay 14, 2026EDGAR
SC 13G/AamendedFMR LLC and 1 other reporting personMay 6, 2026EDGAR
8-KApr 30, 2026EDGAR
10-QAIAlnylam reports a transformational quarter with revenue up 96% and a swing to $206M net income, alongside an ambitious Alnylam 2030 strategy.Apr 30, 2026EDGAR
SC 13GVanguard Capital ManagementApr 29, 2026EDGAR
4McLaughlin MelissaChief Human Resources OfficerApr 7, 2026EDGAR
SC 13G/AamendedThe Vanguard GroupMar 26, 2026EDGAR
4Garg PushkalEVP Chief R&DMar 6, 2026EDGAR
4Greenstreet YvonneChief Executive OfficerMar 6, 2026EDGAR
4Poulton Jeffrey V.EVP, Chief Financial OfficerMar 6, 2026EDGAR
4Tanguler TolgaEVP, Chief Commercial OfficerMar 6, 2026EDGAR
4Fitzgerald Kevin JosephCSO & EVP, Head of ResearchMar 6, 2026EDGAR
4Poulton Jeffrey V.EVP, Chief Financial OfficerMar 5, 2026EDGAR
4Garg PushkalEVP Chief R&DMar 5, 2026EDGAR
4Fitzgerald Kevin JosephCSO & EVP, Head of ResearchMar 5, 2026EDGAR
4Tanguler TolgaEVP, Chief Commercial OfficerMar 5, 2026EDGAR
4SUPRAN BRYANEVP, CLO and SecretaryMar 5, 2026EDGAR
4Greenstreet YvonneChief Executive OfficerMar 5, 2026EDGAR
8-KMar 4, 2026EDGAR
4Greenstreet YvonneChief Executive OfficerMar 2, 2026EDGAR
4Poulton Jeffrey V.EVP, Chief Financial OfficerMar 2, 2026EDGAR
4Tanguler TolgaEVP, Chief Commercial OfficerMar 2, 2026EDGAR
4Garg PushkalEVP Chief R&DMar 2, 2026EDGAR
4Fitzgerald Kevin JosephCSO & EVP, Head of ResearchFeb 25, 2026EDGAR
4Garg PushkalEVP Chief R&DFeb 18, 2026EDGAR
4Greenstreet YvonneChief Executive OfficerFeb 18, 2026EDGAR
4Tanguler TolgaEVP, Chief Commercial OfficerFeb 18, 2026EDGAR
4Fitzgerald Kevin JosephCSO & EVP, Head of ResearchFeb 18, 2026EDGAR
4Poulton Jeffrey V.EVP, Chief Financial OfficerFeb 18, 2026EDGAR
10-KAIStrongly positive tone driven by first-ever profitability, 65% revenue growth and positive operating cash flow, with assertive 2026 expectations and the Alnylam 2030 targets.Feb 12, 2026EDGAR
8-KFeb 12, 2026EDGAR
4Garg PushkalEVP Chief R&DJan 14, 2026EDGAR
4Greenstreet YvonneChief Executive OfficerJan 14, 2026EDGAR
4Poulton Jeffrey V.EVP, Chief Financial OfficerJan 14, 2026EDGAR
4Tanguler TolgaEVP, Chief Commercial OfficerJan 14, 2026EDGAR
4Fitzgerald Kevin JosephCSO & EVP, Head of ResearchJan 14, 2026EDGAR
8-KJan 12, 2026EDGAR
8-KDec 11, 2025EDGAR
8-KDec 3, 2025EDGAR
4Greenstreet YvonneChief Executive OfficerDec 1, 2025EDGAR
4Fitzgerald Kevin JosephCSO & EVP, Head of ResearchNov 19, 2025EDGAR
4Greenstreet YvonneChief Executive OfficerNov 14, 2025EDGAR
SC 13G/AamendedAbigail P. Johnson and 1 other reporting personNov 5, 2025EDGAR
8-KAIAlnylam reported Q3 2025 total net product revenues of $851 million, up 103% year-over-year, driven by TTR franchise revenues of $724 million (135% growth) led by AMVUTTRA's ATTR-CM launch.Oct 30, 2025EDGAR
10-QAIAlnylam's MD&A is markedly positive, reflecting a swing to profitability, 149% quarterly revenue growth, and multiple product approvals and clinical milestones.Oct 30, 2025EDGAR

SEC filings for companies related to ALNY

INCYINCYTE CORPMRNAModerna, Inc.BIIBBIOGEN INC.VRTXVERTEX PHARMACEUTICALS INC / MAREGNREGENERON PHARMACEUTICALS, INC.GILDGILEAD SCIENCES, INC.AMGNAMGEN INCLLYELI LILLY & Co

Never miss a ALNY filing.

Get an email when ALNY files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.

Free foreverNo account requiredOne-click unsubscribe

Protected by reCAPTCHA. Privacy & Terms

Source: SEC EDGAR.